Elanco Execs Bulk Up Stakes as New Canine Skin Drug Sparks Insider Confidence Flashy Buying Surge Drives Stock Up 0.01%—What It Means for Investors
Insider buying spurs confidence in Elanco’s dermatology pipeline, with executive purchases amid a volatile market suggesting long‑term growth prospects.
3 minutes to read





